I think its worth holding for 18 months
the sell down to lower levels last 18 months was based on no news ( I did trade some also ...but I am LT holding more than I traded as I dont want to pay CGT if the price went up earlier due to 6 months to results)
the biggest part of this as someone alluded to is that there is no competitor since 1970-something and that market is huge (I think 4 billion annually from memory)
but if you do the ground work on Glycotecx which was originally owned by Novogen (NRT ASX) which is the same product they took over and have been doing the trials on ever since - there is a ton of interesting information.if you go to that prospects on the S-1 us listing when it went to the Nasdaq via Novogen and was withdrawn ....the scope is way different.. Note this is OLD and not what they are in trials for - but it is the same product essentially
I took the `glycogen from NRT as their IP from their company timeline from 2007 on the TIS website - I presume those trials would take forever but I think the product seems to be more of a powerhouse than scars etc
The markets for human wound healing and tissue repair products are large and growing. Initially, we plan to address the market for chronic wound care with our lead product candidate, MG3601, for the treatment of trophic ulcers. Trophic ulcers, in particular venous stasis ulcers, are characteristically difficult and slow to heal, often requiring care over periods of several months to as long as many years. In severe cases amputation is the only surgical intervention available to treat these ulcers, in particular, those stemming from arterial insufficiency associated with diabetes. Trophic ulcers primarily occur in patients that are past middle age and represent a significant community health problem. For example, according to the wound care trade publication, Advances in Skin & Wound Care, the estimated per-episode cost of care for venous stasis ulcers can exceed $40,000. To further illustrate the importance of this market, the Centers for Disease Control and Prevention, or CDC, estimates that approximately 85% of lower extremity amputations in diabetic patients in the United States are preceded by a foot ulcer. We believe that there is a large unmet medical need for human wound healing and tissue repair products such as MG3601 that have the potential to accelerate the wound healing process significantly.The markets for human wound healing and tissue repair products are large and growing. Initially, we plan to address the market for chronic wound care with our lead product candidate, MG3601, for the treatment of trophic ulcers. Trophic ulcers, in particular venous stasis ulcers, are characteristically difficult and slow to heal, often requiring care over periods of several months to as long as many years. In severe cases amputation is the only surgical intervention available to treat these ulcers, in particular, those stemming from arterial insufficiency associated with diabetes. Trophic ulcers primarily occur in patients that are past middle age and represent a significant community health problem. For example, according to the wound care trade publication, Advances in Skin & Wound Care, the estimated per-episode cost of care for venous stasis ulcers can exceed $40,000. To further illustrate the importance of this market, the Centers for Disease Control and Prevention, or CDC, estimates that approximately 85% of lower extremity amputations in diabetic patients in the United States are preceded by a foot ulcer. We believe that there is a large unmet medical need for human wound healing and tissue repair products such as MG3601 that have the potential to accelerate the wound healing process significantly.
(20min delay)